| http://www.w3.org/ns/prov#value | - candidates through preclinical development, the most advanced of which target chemokine receptors involved in atopic dermatitis, inflammatory bowel disease, or IBD, including ulcerative colitis, liver inflammation, psoriasis, and RA. Traficet-EN, our most advanced drug candidate, is intended to control the inflammatory response underlying IBD by
|
